Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.71 |
| ▸ | CNR1 | P21554 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL859363 | 0.91 | CNR2 (0.71) | CNR2CNR1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL9897576 | 0.83 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL843288 | 0.81 | CNR2 (0.66) | CNR2CNR1ALDH1A1 | |
| SCHEMBL9894674 | 0.80 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL843916 | 0.80 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL859046 | 0.79 | CNR2 (0.78) | CNR2CNR1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL859362 | 0.75 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL843936 | 0.71 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL843701 | 0.70 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL9895640 | 0.70 | CNR2 (1.00) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE (FR) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149735-A1 | 1,4-Dihydropyridine Derivatives and Their Uses | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885LMNA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.